Genome-wide methylation analysis of circulating tumor DNA: A new biomarker for recurrent glioblastom

Lin Dai; Zhihui Liu; Yi Zhu; Lixin Ma

doi:10.1016/j.heliyon.2023.e14339

Genome-wide methylation analysis of circulating tumor DNA: A new biomarker for recurrent glioblastom

Heliyon. 2023 Mar 15;9(3):e14339. doi: 10.1016/j.heliyon.2023.e14339. eCollection 2023 Mar.

Authors

Lin Dai¹, Zhihui Liu², Yi Zhu¹, Lixin Ma^{3

4}

Affiliations

¹ Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou, 256603, PR China.
² Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
³ Department of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
⁴ Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, PR China.

Abstract

Background: Glioblastoma (GBM) is a malignant tumor with a short survival and poor prognosis and a lack of clinically validated biomarkers for diagnosis and prognosis.

Methods: We collected cerebrospinal fluid (CSF) samples and normal CSF sample from recurrent GBM patients and paired tissue samples. Methylation profiles of CSF circulating tumor DNA (ctDNA) and transcriptional profiles of tumor tissues were analyzed. The China Glioma Genome Atlas (CGGA) database and Gene Expression Omnibus (GEO) was used for data analysis.

Results: Lasso analysis and multiplex Cox analysis were performed using intersecting genes of differentially methylated regions and differentially expressed genes. 8 hub genes were screened to construct diagnostic and prognostic models. Based on these 8 hub genes, the diagnostic (AUC = 0.944) and prognostic (3-years, AUC = 0.876) models were accurate.

Conclusions: In this study, 8 hub genes were identified for the diagnosis and prognosis of recurrent GBM, providing new biomarkers for the clinical study of recurrent GBM.

Keywords: CSF; Liquid biopsy; Methylation; Recurrent glioblastoma; ctDNA.